Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Escitalopram price philippines 2025?

See the DrugPatentWatch profile for Escitalopram

How much is escitalopram in the Philippines in 2025?

Pricing in 2025 depends on the brand (e.g., generic vs. branded escitalopram), tablet strength (commonly 5 mg, 10 mg, 20 mg), and the pharmacy or online seller. Escitalopram is widely stocked, but the exact price can vary significantly by provider and whether it is sold as a branded product or a generic.

If you tell me your target strength (5 mg, 10 mg, or 20 mg) and your preferred option (brand vs. generic, and pack size), I can help you narrow down what to ask for and what price range to expect.

Where to check the most accurate 2025 price in PH

For current local pricing, the most reliable places to check are:
- Major pharmacy chains in-store or via their online listings
- Credible online pharmacies that show unit price and exact formulation
- Doctor-prescription-based pharmacies that carry generics under multiple supplier names

Prices often change with supply and promotions, so checking the same month (or even the same week) usually gives the best answer.

Is there a big price difference between brand and generic?

Yes. In most markets, generic escitalopram typically costs less than branded versions, and the gap can be large depending on the strength and tablet count. If affordability is the goal, asking for the generic equivalent (escitalopram) at your exact dose is usually the fastest way to reduce cost.

What can change the total cost (dose and pack size)

Even if the “per tablet” price looks similar, total monthly cost changes based on:
- Your daily dose (5 mg vs 10 mg vs 20 mg)
- Tablets per pack (e.g., 14, 28, 30, 60)
- Whether you’re splitting a higher-dose tablet or buying the exact dose

If you share your dose and how many tablets per month you use, I can help estimate the monthly budget and what pack size is most economical.

Prescription and substitution in the Philippines

Escitalopram is commonly treated as prescription medicine. In practice, substitution to a generic with the same active ingredient and strength may be allowed depending on the pharmacy and the prescription wording. If you’re trying to keep costs down, ask the pharmacist whether they can dispense an equivalent generic for your prescribed dose.

If you’re comparing prices: what to ask the pharmacy

Bring or read out:
- “Escitalopram” (active ingredient)
- Exact strength (5 mg / 10 mg / 20 mg)
- Form (tablet)
- Quantity/pack size you need for one month

That avoids the common issue where you’re comparing different strengths or different tablet counts.

To give you a specific 2025 price range

Reply with:
1) your dose (5 mg, 10 mg, or 20 mg),
2) how many tablets you want (or monthly use), and
3) whether you want generic or a specific brand name.

Then I’ll tailor the guidance to your exact scenario and help you figure out what a reasonable 2025 price target would be in PH.

Sources: none provided.



Other Questions About Escitalopram :

escitaloprám 10 mg pill Oxalato de escitalopram precio? Has your drowsiness increased on escitalopram? Have you experienced less fatigue since taking escitalopram? Who has the patent for escitalopram? Escitalopram recent news or updates 2025 2026? How does escitalopram affect your energy levels daily?

AI-Drug Label Prescribing Information Alignment Report

95
95%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI claim is directly supported by the label’s Boxed Warning, Warnings and Precautions (5.1), and Patient Counseling (Section 17), including the pediatric/young adult suicidal thoughts/behaviors risk, monitoring, and counseling emphasis during initial therapy and dose changes.


Category Scores

Indication
100
Excellent
Dosage
95
Excellent
Indication
100
Excellent
Dosage
95
Excellent

Accurate Statements

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.
Section 0 (Boxed Warning): “Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.”
Clinicians should closely monitor patients for clinical worsening and for emergence of suicidal thoughts and behaviors.
Section 0 (Boxed Warning) and Section 5.1: “Closely monitor…” / “Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors.”
Counseling families/caregivers to monitor for emergence of suicidal ideation/behavior is appropriate, especially during initial therapy and when the dose is adjusted up or down.
Section 5.1: “Counsel family members or caregivers…” and “especially during the initial few months… and at times of dosage changes.”; Section 17: “especially during treatment and when the dose is adjusted up or down…”

Unsupported Statements


Contradictions


Important Omissions

Consider changing the therapeutic regimen (including possibly discontinuing escitalopram oxalate) in patients with persistently worse depression or emergent suicidal thoughts/behaviors.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The claim accurately reflects the label’s risk and key monitoring/counseling instructions for suicidal thoughts/behaviors; a moderate omission is the label’s guidance about considering regimen changes/discontinuation in certain scenarios.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Did not mention the label’s recommendation to consider changing the therapeutic regimen (including possibly discontinuing) for persistently worse depression or emergent suicidal thoughts/behaviors.

Suggested Improvement
Add the label-consistent statement from Section 5.1: consider changing the therapeutic regimen, including possibly discontinuing escitalopram oxalate, in patients with persistently worse depression or emergent suicidal thoughts/behaviors.